Aditxt announced a transaction to separate its subsidiary Ignite Proteomics into an independent public company named Ignite Proteomics Inc., while Aditxt remains listed on Nasdaq. Ignite focuses on precision oncology, particularly breast cancer, and aims to expand its tumor type coverage. The deal is intended to unlock value for Ignite and provide it with better access to growth capital for commercialization and clinical efforts. Aditxt shares fell about 28% in premarket trading amid weak market sentiment for volatile microcaps, with the stock deeply oversold technically. The transaction awaits shareholder and regulatory approvals before completion.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
Gooch & Housego, a UK-listed photonics company specializing in precision optics for aerospace and defence, has agreed to a £345.6 million takeover by US private equity firm Arlington Capital Partners. The offer values the company at a 41.3% premium t...
Aave DAO has proposed an innovative mobile app that integrates fiat currency deposits, self-custody, and decentralized finance (DeFi) lending in one platform. This app allows users to convert fiat to stablecoins and earn yields without needing extern...
Analysts expect Netflix to report $12.6 billion in revenue for Q2 and $51.3 billion for the full year 2026. The operating margin forecast has been revised down from 33% to 32% due to anticipated higher expenses, with an expected operating profit of $...
